Polaryx Therapeutics, Inc. PLYX
—
2.09
(0.05)
(2.34%)
as of 25 Sep
- Market cap
- $106.7M
- P/E
- 0.0×
Follow PLYX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | — | 0.00% | |
| — | — | 0.00% | (169.05%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (91.27%) | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.16) | (0.17) | |
Free Cash Flow |
— | (8.08) | (7.57) | (8.23) | |
Piotroski F-Score |
— | — | — | 1.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | (83.27%) | (136.03%) | (36.63%) | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.82 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (0.16) | (0.17) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates